Search

Displaying results 2111 - 2120 of 6949 in total
  1. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. … safer for use in patients with contraindications to standard therapy.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  2. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl

  3. Drug

    Dimethyl fumarate

    go.drugbank.com/drugs/DB08908
    ApprovedInvestigational

    Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. … [A253917] Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.[A253917]

  4. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    The acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting. … Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections [L2570], [L2571].

  5. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes. … [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.

  6. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  7. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals … PHN can last for days, months, or even years following resolution of shingles.

    Categories: Antiinfectives for Systemic Use
  8. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    that is less frequent than that for turoctocog alfa. … As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients

  9. Target

    Alpha-1 adrenergic receptors

    go.drugbank.com/bio_entities/BE0004863
    TargetHumans

    Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenge...

    Polypeptides: Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptorSynonyms: Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c
  10. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics